Sort by
Refine Your Search
-
Category
-
Country
-
Employer
- Harvard University
- University of British Columbia
- National University of Singapore
- Indiana University
- UNIVERSITY OF HELSINKI
- University of Michigan
- City of Hope
- University of Oslo
- King's College London
- Max Planck Institute for Human Development, Berlin
- Nanyang Technological University
- The Ohio State University
- UiT The Arctic University of Norway
- University of Leeds
- University of Maryland, Baltimore
- University of Oxford
- Zintellect
- BU Pulmonary
- Cori Institute of Molecular and Computational Metabolism
- Dana-Farber Cancer Institute (DFCI)
- Duke-NUS
- Eisbach Bio GmbH
- Fundació Hospital Universitari Vall d'Hebron- Institut de recerca
- Icelandic Heart Association
- Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S)
- Lawrence Berkeley National Laboratory
- Margaret M Redfield
- Max Planck Institute of Biochemistry, Martinsried
- Mayo Clinic
- Monash University
- Northeastern University
- Research Center for Molecular Medicine (CeMM), ÖAW
- SciLifeLab
- Tampere University
- The University of Edinburgh;
- The University of Queensland
- Tokyo University of Science
- UT Health San Antonio Long School of Medicine
- University of Aberdeen;
- University of Bergen
- University of Birmingham
- University of California
- University of Colorado
- University of Helsinki
- University of Michigan (U-M)
- University of Michigan - Ann Arbor
- University of New South Wales
- University of North Carolina at Charlotte
- University of Oklahoma Health Campus
- University of Otago
- University of Texas Rio Grande Valley
- Université de Strasbourg
- 42 more »
- « less
-
Field
-
may contribute to projects involving: multi-omics analyses (single-cell, cell-free RNA/DNA, methylation, proteomics); biomarker discovery for pregnancy complications and neonatal outcomes; computational
-
Microproteins are an emerging and largely unexplored layer of the human proteome, offering major opportunities to uncover new biology and therapeutic targets. The Ho Lab is seeking an outstanding
-
for therapeutic intervention. You will bring extensive experience in structural proteomics to the role, and utilise and further develop advanced structural proteomics approaches including chemical crosslinking mass
-
and proteomic profiling. Qualifications and personal qualities: The applicant must hold a Norwegian PhD or an equivalent degree within neurobiology/ tumor biology, or equivalent in a relevant field of
-
. The Institute hosts several shared research infrastructures, including cutting-edge facilities for genomic and transcriptomic sequencing, cryogenic electron microscopy (cryo-EM), light microscopy, and proteomics
-
cell culture and 3D in vitro models; position the Celvivo system or similar rotational system. Experience with secretome/secretomics, extracellular vesicles/exosomes, proteomics, or related molecular
-
with secretome/secretomics, extracellular vesicles/exosomes, proteomics, or related molecular approaches. Documented experience in optimizing, validating, and executing high-multiplex protein panels
-
and single-cell omics (transcriptomics, proteomics, epigenomics, metabolomics, meta-transcriptomics, etc.) data. Independently carry out computational and bioinformatics analysis for large-scale spatial
-
cancer relapse and targeted therapy response. Responsibilities* Process and preprocess raw data across genomics, proteomics, and epigenomics platforms, including DNA-seq, RNA-seq, ChIP-seq, ATAC-seq, and
-
the 36 months immediately before the March 1st, 2027. Experience and knowledge: Required: Experience with next-generation sequencing, molecular diagnostics and/or transcriptomic, proteomic or metabolomic